MedDataX Logo

Intestinal Mesenchymal Stem Stells and Inflammatory Bowel Diseases

NCT ID: NCT03115749

Last Updated: 2021-12-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

2 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-11-21

Study Completion Date

2019-02-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The exact origin of inflammatory bowel disease (IBD) is still unknown. The current hypothesis is that IBD is secondary to an abnormal intestinal immun response directed to all or part of the intestinal flora in genetically predisposed individuals. Several experimental studies have demonstrated the ability of mesenchymal stem cells (MSCs) from bone marrow or adipose tissue origin to control intestinal inflammation in animal models. However, to date, there are no data regarding the functions of resident MSCs in the colon and small intestine of IBD patients. We hypothesize that dysfunction of resident intestinal MSCs contributes to the disruption of intestinal homeostasis in patients with IBD causing the development of intestinal inflammation. The aim of this research project is to identify, describe and characterize at the molecular and functional level MSCs of the colon and small intestine of patients with Crohn's disease and ulcerative colitis and to compare them with a control population.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary and secondary objectives:

Main Objective: Characterize morphologically, molecularly and functionally the MSCs of colon and small intestine of patients with IBD and compared to MSCs of colon and small intestine of control patients.

Secondary objectives: To study the reaction of colon and small intestine MHC in patients with IBD following stimulation with bacterial compounds.

Methodology:

Clinical study exploratory translational physiopathological. Two groups of patients with Crohn's disease and ulcerative colitis who require colonoscopy or surgery for intestinal resection will be included. These two groups will be compared to a control group consisting of patients requiring colonoscopy for screening or intestinal resection for colorectal cancer or diverticulum.

Intestinal sampling by biopsy during the colonoscopy or with surgical specimen during the surgery will be performed to isolate the MSCs.

The outcome measures will be a qualitative and quantitative analysis of MSCs by immunohistochemistry, immunofluorescence, cell proliferation and differentiation, production of pro- and anti-inflammatory cytokines in the basal state and after bacterial stimulation.

Total of 60 patients (20 in groups, 15 with colonoscopy and 5 with surgical specimens).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammatory Bowel Diseases

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Crohn's disease ulcerative colitis mesenchymal stem cells intestinal inflammation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Crohn's disease patient group

Intestinal biopsies during colonoscopy or biopsies taken on surgical specimen after intestinal resection

Group Type OTHER

Intestinal biopsies during colonoscopy

Intervention Type OTHER

Intestinal biopsies during colonoscopy

Biopsies taken on surgical specimen

Intervention Type OTHER

biopsies taken on surgical specimen after intestinal resection

Ulcerative colitis patient group

Intestinal biopsies during colonoscopy or biopsies taken on surgical specimen after intestinal resection

Group Type OTHER

Intestinal biopsies during colonoscopy

Intervention Type OTHER

Intestinal biopsies during colonoscopy

Biopsies taken on surgical specimen

Intervention Type OTHER

biopsies taken on surgical specimen after intestinal resection

Control group

Intestinal biopsies during colonoscopy or biopsies taken on surgical specimen after intestinal resection

Group Type OTHER

Intestinal biopsies during colonoscopy

Intervention Type OTHER

Intestinal biopsies during colonoscopy

Biopsies taken on surgical specimen

Intervention Type OTHER

biopsies taken on surgical specimen after intestinal resection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intestinal biopsies during colonoscopy

Intestinal biopsies during colonoscopy

Intervention Type OTHER

Biopsies taken on surgical specimen

biopsies taken on surgical specimen after intestinal resection

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* For IBD patients :

* Age between 18 and 75 year old
* Diagnosis of Crohn's disease or ulcertaive colitis according to internationla guidelines
* Endoscopically active disease
* Indication for colonoscopy or intestinal resection according to standard of care
* Written inform consent
* For control patients :

* Age between 18 and 75 year old
* Indication for screening colonoscopy for irritable bowel syndrome, diverticulum or colorectal cancer surveillance according to standard of care
* Indication for intestinal resection for diverticulum or colorectal cancer according to standard of care
* Written inform consent

Exclusion Criteria

* For IBD patients :

* Active intestinal infection
* Confirmed intestinal parasitosis
* Intestinal stoma
* For control patients :

* Active intestinal infection
* Confirmed intestinal parasitosis
* Intestinal inflammation at colonoscopy
* Chronic intestinal inflammation on biopsies
* Absence of healthy tissue on surgical specimen
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Montpellier

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Guillaume Pineton de Chambrun

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Montpellier

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hopital St Eloi

Montpellier, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

9755

Identifier Type: -

Identifier Source: org_study_id